SRU Biosystems is a global provider of novel, label-free, detection tools used in drug discovery and life sciences research. Our patented BIND® technology rapidly analyzes biomolecular interactions of cells, proteins, genomic materials, peptides, antibodies and small molecule compound libraries. BIND technology represents a fundamental advance in the ability to monitor label-free biological interactions with high sensitivity and high throughput.
Molecular Insight Pharmaceuticals is a clinical-stage biopharmaceutical company and a pioneer in the emerging field of molecular medicine. The Company is focused on the discovery and development of therapeutic radiopharmaceuticals and targeted molecular imaging agents for use in oncology and cardiology.
Merrimack Pharmaceuticals are dedicated to the discovery and development of innovative therapies for the treatment of autoimmune disease and cancer. Merrimack is advancing a robust pipeline of clinical and early-stage biologics that represent the next generation of patient-directed, targeted therapies.